CIA
SAGE

CSat Investment Advisory’s Sage Therapeutics SAGE Stock Holding History

CSat Investment Advisory’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-151
Closed -$4K – 1162
2020
Q1 		$4K Buy
151
+22
+17% +$1.27K ﹤0.01% 1041
2019
Q4 		$9K Buy
129
+16
+14% +$1.97K ﹤0.01% 1013
2019
Q3 		$16K Buy
113
+20
+22% +$3.35K 0.01% 780
2019
Q2 		$17K Buy
+93
New +$15.9K 0.01% 725

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CSat Investment Advisory's SAGE Position: Q2 2020 in Review

CSat Investment Advisory sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 151 shares — an estimated $4K sold.

CSat Investment Advisory first reported a position in SAGE in Q2 2019 and held it in 4 quarters. The position peaked at $17K in Q2 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

  • CSat Investment Advisory reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 151 Sage Therapeutics shares in Q2 2020, an estimated $4K.
  • CSat Investment Advisory first reported a position in Sage Therapeutics in Q2 2019 and held it in 4 quarters.
  • CSat Investment Advisory's Sage Therapeutics position peaked at $17K in Q2 2019.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on CSat Investment Advisory's 13F filing for Q2 2020, filed 7 Aug 2020.